

## SPECIALTY GUIDELINE MANAGEMENT

### MENOPUR (menotropins for injection)

#### POLICY

##### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

###### FDA-Approved Indications

Menopur is indicated for development of multiple follicles and pregnancy in ovulatory women as part of an assisted reproductive technology cycle.

All other indications are considered experimental/investigational and are not a covered benefit.

##### II. MEDICAL BENEFIT ALIGNMENT

Specialty Guideline Management coverage review will be bypassed for drug(s) being requested for a procedure that has been approved under a member's medical benefit plan. Such members will be exempt from the requirements in Sections III and IV. A medical authorization number and confirmation of the approved procedure(s) will be required.

***NOTE: Some plans may opt-out of medical benefit alignment. Members receiving coverage under such plans must meet the requirements in Sections III and IV.***

##### III. CRITERIA FOR INITIAL APPROVAL

###### **Follicle stimulation**

Authorization of 12 months may be granted for members with infertility prescribed menotropins who meet any of the following criteria:

1. Member has completed three or more previous cycles of clomiphene, or
2. Member has a risk factor for poor ovarian response to clomiphene, or
3. Member has a contraindication or exclusion to clomiphene, or
4. Member is 37 years of age or older

##### IV. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

##### V. REFERENCES

1. Menopur [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.; February 2014.
2. Practice Committee of the American Society of Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. *Fertil & Steril*. 2013;100:341-348.